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A B S T R A C T
Cancer cells are able to survive under conditions that cause endoplasmic reticulum stress (ER-stress), and can
adapt to this stress by upregulating cell-survival signalling pathways and down-regulating apoptotic pathways.
The cellular response to ER-stress is controlled by the unfolded protein response (UPR). Small Rho family
GTPases are linked to many cell responses including cell growth and apoptosis. In this study, we investigate the
function of small GTPases in cell survival under ER-stress. Using siRNA screening we identify that RAC1 pro-
motes cell survival under ER-stress in cells with an oncogenic N92I RAC1 mutation. We uncover a novel con-
nection between the UPR and N92I RAC1, whereby RAC1 attenuates phosphorylation of EIF2S1 under ER-stress
and drives over-expression of ATF4 in basal conditions. Interestingly, the UPR connection does not drive re-
sistance to ER-stress, as knockdown of ATF4 did not aﬀect this. We further investigate cancer-associated kinase
signalling pathways and show that RAC1 knockdown reduces the activity of AKT and ERK, and using a panel of
clinically important kinase inhibitors, we uncover a role for MEK/ERK, but not AKT, in cell viability under ER-
stress. A known major activator of ERK phosphorylation in cancer is oncogenic NRAS and we show that
knockdown of NRAS in cells, which bear a Q61 NRAS mutation, sensitises to ER-stress. These ﬁndings highlight a
novel mechanism for resistance to ER-stress through oncogenic activation of MEK/ERK signalling by small
GTPases.
1. Introduction
Oncogenesis and uncontrolled cancer cell division often lead to
conditions that perturb protein folding and induce endoplasmic re-
ticulum stress (ER-stress) [1]. These conditions, such as protein over-
expression and hypoxia, can lead to cell death if cancer cells do not
adapt. Cell fate under ER-stress is controlled by the unfolded protein
response (UPR), a transcriptional programme that promotes increased
protein folding capacity and adaptation to ER-stress or, if stress is not
resolved, activates apoptotic pathways [2]. There are three ubiqui-
tously expressed controlling arms to the UPR: endoplasmic reticulum to
nucleus signalling 1 (ERN1, hereafter referred to by its common name,
IRE1); eukaryotic translation initiation factor 2-alpha kinase 3
(EIF2AK3, hereafter referred to by its common name, PERK); and cyclic
AMP-dependent transcription factor ATF-6 alpha (ATF6). IRE1 bears a
kinase domain and a ribonuclease (RNase) domain, and dimerizes/
oligomerizes upon activation by ER-stress. The main target of the IRE1
RNase domain is the mRNA coding for X-box-binding protein 1 (XBP1)
[3]. IRE1 cleaves full length XBP1 mRNA (XBP1u) preceding its non-
conventional splicing within the cytoplasm. Spliced XBP1 mRNA
(XBP1s) codes for the active XBP1 transcription factor which promotes
adaptation to stress [4]. PERK is a kinase that dimerizes upon activation
by ER-stress [5] and phosphorylates its major target, eukaryotic
translation initiation factor 2 subunit alpha (EIF2S1). This phosphor-
ylation event attenuates protein translation relieving the protein
folding burden within the ER and promoting cell survival [6]. However,
translation of pro-apoptotic transcription factors such as cyclic AMP-
dependent transcription factor ATF-4 (ATF4) and DNA damage-in-
ducible transcript 3 (DDIT3) continues, promoting apoptosis if ER-stress
is not resolved [7]. ATF6 is a transcription factor that is held within the
ER membrane in resting conditions. Upon ER-stress, ATF6 is released
from the ER and traﬃcs to the Golgi apparatus where it is cleaved,
releasing the active transcription factor to translocate to the nucleus. A
major function of ATF6 is to promote adaptation to stress by increasing
expression of pro-survival factors [8]. Under acute ER-stress, the UPR
promotes cell survival and adaptation. However, this function is su-
perseded by pro-apoptotic signalling pathways (e.g. ATF4 and DDIT3)
under prolonged ER-stress [9].
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Oncogenic signalling in cancer cells promotes the avoidance of
apoptosis through multiple mechanisms [10]. A key family of signalling
proteins that has been linked to tumorigenesis and evasion of apoptosis
is the Rho GTPases—a family of 20 GTPases, several of which have been
found to be overexpressed or mutated in cancer [11]. One of the most
well-characterised Rho GTPases is Ras-related C3 botulinum toxin
substrate 1 (RAC1). Both overexpression and mutation have been de-
scribed in cancer, most notably, RAC1 P29S mutation is a recurrent
mutation in melanoma [12]. A major role of RAC1 is as a master reg-
ulator of cell migration, which is of particular importance to metastasis
and angiogenesis in cancer [13]. RAC1 has also been linked to the
strongly cancer-associated kinase signalling pathways involving iso-
forms of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), RAC-
alpha serine, threonine protein-kinase (AKT), and serine/threonine
protein-kinase mTOR (MTOR) (hereafter referred to as the PI3K/AKT/
MTOR pathway) [14], and Raf proto-oncogene (RAF)/mitogen-acti-
vated protein kinase kinase (MEK)/Mitogen activated protein kinase
(ERK) (hereafter referred to as the RAF/MEK/ERK pathway) [12, 15].
Among many other eﬀects, these pathways are involved in the avoid-
ance of apoptosis and drug resistance [16]. RAC1 signalling has also
recently been linked to drug resistance [17] and P29S mutant RAC1
promotes resistance to inhibition of RAF and MEK [18].
The roles of Rho GTPases in ER-stress signalling and the UPR have
not yet been fully established. In Caenorhabditis elegans, knockout of the
Rho GTPase CRP-1 impairs the UPR and leads to stress-sensitivity [19],
suggesting that human Rho GTPases may also aﬀect cell survival under
ER-stress. The major function of the Rho GTPase family is in control of
cell migration and important components of this process are actin and
myosin [20]. Myosin IIB has recently been implicated in the oligo-
merization and clustering of IRE1 [21] suggesting that upstream Rho
GTPases may feed into this process. In the present work, we aimed to
clarify the role of Rho GTPases in cancer cell survival under ER-stress.
Taking an siRNA approach we found that RAC1 knockdown in HT-1080
human ﬁbrosarcoma cells that express N92I oncogenic RAC1 sensitises
them to ER-stress. Investigating the UPR in these cells, we found that
knockdown of RAC1 reduced the expression of ATF4 mRNA and pro-
tein, and also reduced phosphorylation of EIF2S1. However, these ef-
fects on UPR signalling were not responsible for the increased sensi-
tivity to ER-stress. Further investigation of kinase signalling pathways
showed that RAC1 knockdown impairs the basal phosphorylation of
AKT, MEK1/2 and ERK1/2. Using clinically relevant PI3K/AKT/MTOR
or RAF/MEK/ERK inhibitors we found that inhibition of MEK/ERK, but
not PI3K/AKT/MTOR pathways, caused sensitivity to ER-stress. The B-
Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor GDC-
0879 induced paradoxical ERK1/2 activation as previously described
[22], and partially rescued the eﬀect of RAC1 knockdown. Because
oncogenic NRAS also drives ERK signalling in cancer, we tested the
eﬀect of NRAS knockdown in HT-1080 and RD soft tissue sarcoma cell
lines (which both contain a Q61 NRAS mutation) and found that NRAS
knockdown sensitised cells to ER-stress. We conclude that oncogenic
RAC1 and NRAS mutations protect cancer cells from ER-stress by ac-
tivating ERK1/2.
2. Materials and methods
2.1. Cell culture and induction of ER-stress
HT-1080 and RD soft tissue sarcoma cell lines were obtained from
the European Collection of Cell Cultures and the American Type Culture
Collection, respectively. Cells were used within two months of thawing
and were authenticated by the suppliers. Cells were maintained at
37 °C, 5% CO2, in Minimal Essential Media supplemented with 1.87mM
Glutamax (ThermoFisher Scientiﬁc) and 10% heat-inactivated foetal
bovine serum (Life Technologies). ER-stress was induced by the addi-
tion of 2mM dithiothreitol (DTT) or 20 μg/ml tunicamycin (Tm).
2.2. siRNA transfection
Cells were transfected at the time of seeding using Lipofectamine
RNAiMAX (ThermoFisher Scientiﬁc) at a ﬁnal ratio of 0.5 μl
RNAiMAX:600 μl medium. siRNA was used at a concentration of 2 nM
for pools and single oligomers, and 2 nM per oligomer for combinations
of two oligomers. Downstream experiments were performed 48 h after
transfection. siRNA was obtained from Qiagen (siCtrl) or Dharmacon
(all other siRNA). Product numbers for pools of four oligos (Used for
Fig. 1A) are as follows: RHOA, M-003860-03; RHOB, M-008395-04;
RHOC, M-008555-01; RHOD, M-008940-00; RHOF, M-008316-00;
RHOG, M-008995-00; RHOH, M-008804-00; RHOJ, M-010367-01;
RHOQ, M-009943-01; RHOU, M-009882-00; RHOV, M-006374-02;
RAC1, M-003560-06; RAC2, M-007741-01; RAC3, M-008836-02;
Fig. 1. Oncogenic RAC1 protects HT-1080
human ﬁbrosarcoma cells from ER-stress. A
and B, Relative viability (WST-1 assay) of
RD cells (A) and HT-1080 cells (B) after
knockdown using pools of four siRNA
against the indicated targets followed by
treatment with 2mM DTT for 24 h. Data
show relative viability of DTT-treated com-
pared to untreated cells for each siRNA. C–F,
Relative viability (WST-1 assay) of RD cells
(C and D) and HT-1080 cells (E and F) after
knockdown using the indicated individual
siRNA followed by treatment with 2mM
DTT (C and E) or 20 μg/ml Tm (D and F) for
24 h. Data show relative viability of ER-
stressed (DTT or Tm) compared to un-
stressed cells for each siRNA. G and H,
Representative western blots showing ex-
pression of RAC1 and β-actin loading con-
trol in RD cells (G) or HT-1080 cells (H)
after knockdown using the indicated siRNA
oligomers (-= untransfected, C= siCtrl).
Western blots are representative of three
independent experiments. Bar charts show
means ± S.E.M. of data from three in-
dependent experiments. * p < .05, **
p < .01, *** p < .001, unpaired t-test
comparing to siCtrl, n= 3.
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Cdc42, M-005057-01; RHOBTB1, M-009389-00; RHOBTB2, M-009252-
00; RND1, M-008929-01; RND2, M-009727-01; RND3, M-007794-02;
RHOT1, M-010365-01; RHOT2, M-008340-01; ATF6, M-009917-01;
siCtrl pool, D-001206-14. Product numbers for individual oligomers are
as follows: RAC1_si1, D-003560-07; RAC1_si2, D-003560-08; RAC1_si3,
D-003560-09; RAC1_si4, D-003560-30; PERK_si1, D-004883-02;
PERK_si2, D-004883-05; ATF4_si1, D-005125-01; ATF4_si2, D-005125-
07; ATF4_si3, D-005125-08; ATF4_si4, D-005125-09; NRAS_si1, D-
003919-01; NRAS_si2, D-003919-02; NRAS_si3, D-003919-03;
NRAS_si4, D-003919-04; siCtrl, SI03650318 (Qiagen).
2.3. Inhibitors
The following inhibitors were purchased from Selleck Chemicals,
catalogue numbers as follows: GSK2656157 (hearefter referred to as
PERKi), S7033; pictilisib (GDC-0941), S1065; AZD8055, S1555; apito-
lisib (GDC-0980), S2696; selumetinib (AZD6244), S1008; GDC-0879,
S1104; RO5126766, S7170; SCH772984, S7101. AKT inhibitor VIII
(AKTi VIII) was purchased from Merck Millipore, catalogue number
124018. Concentrations were selected from a dilution series performed
to ensure activity. Concentrations used for all experiments are shown in
Table 1. Cells were treated with inhibitor 1 h prior to induction of ER-
stress.
2.4. Western blotting
For western blotting, cells were lysed in buﬀer containing 1% Triton
X-100, 1% sodium dodecyl sulfate, 150mM NaCl, 5 mM EDTA, 10mM
Tris, pH 7.6, Complete protease inhibitor (Roche) and PhosStop phos-
phatase inhibitor (Roche). Protein concentration was measured by bi-
cinchronic assay (ThermoFisher Scientiﬁc). 5× Reducing sample buﬀer
(300mM Tris pH 6.8; 50% v/v glycerol; 2.5 mg/ml bromophenol blue;
250mg/ml dithiothreitol) was added and lysates were diluted to equal
concentrations. Proteins were separated by SDS-PAGE and transferred
onto PVDF membrane. Membranes were blocked in Tris-buﬀered saline
containing 5% bovine serum albumin for at least 30min, then in-
cubated with antibody overnight at 4 °C. Antibodies used were as fol-
lows: Cell Signaling Technology: PARP1 (#9532), caspase-3 (#9665),
PERK (#3192), phosphorylated EIF2S1 (Serine 51) (#9721), EIF2S1
(#5324), ATF4 (#11815), phosphorylated AKT (Serine 473) (#9271),
AKT (#4691), phosphorylated MEK1/2 (Serine 217/221) (#9154),
MEK1/2 (#8727), phosphorylated ERK1/2 (Threonine 202/Tyrosine
204) (#4376) and ERK1/2 (#9102). Millipore: NRAS (OP25-100UG)
and RAC1 (05-389). ATF6 (ab122897) from Abcam and β-actin
(A5441) from Sigma-Aldrich.
2.5. Antibody arrays
PathScan Stress and Apoptosis Signalling Antibody Array Kits were
purchased from Cell Signaling Technology, product #12923. Cells were
lysed and processed for arrays according to the manufacturer's protocol.
The protein concentration of the lysate was 0.8mg/ml and incubations
were carried out overnight at 4 °C. Arrays were imaged using an
Odyssey Fc imaging system and quantiﬁed using Image Studio software
(LI-COR).
2.6. RNA extraction and quantitive PCR (qPCR)
RNA was extracted and puriﬁed from cells using an RNeasy Plus
Mini kit (Qiagen) according to the manufacturer's protocol. The re-
sulting RNA was used to produce cDNA using qScript cDNA Supermix
(Quantabio). The resulting cDNA was used as a template for TaqMan
real-time PCR assays to determine transcript expression. Reaction vo-
lume was 20 μl. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a housekeeping control for relative quantiﬁcation. The
following TaqMan assays were used: GAPDH, Hs02758991_g1; XBP1u,
Hs02856596_m1; XBP1s, Hs03929085_g1; DDIT3, Hs00358796_g1;
ATF4, Hs00909569_g1; PPP1R15A, Hs00169585_m1; Relative quantity
of transcript was quantiﬁed by normalising ﬁrst to GAPDH, and then to
the measurement from untreated cells using Applied Biosystems 7500
software.
2.7. WST-1 cell viability assays and measurement of sensitivity to stress
Cells were seeded in 96-well plates and treated/transfected as in-
dicated in triplicate wells for each independent experiment. Cells were
subjected to ER-stress for 24 h (or left unstressed), then washed in
medium, and fresh phenol-red-free medium containing WST-1 reagent
(Abcam) was added. Cells were subsequently maintained for 1 h prior to
measuring absorbance at 440 nM. The negative control background
reading was subtracted from all measurements. To measure sensitivity
to stress, ‘Viability after 24 h DTT (relative to unstressed)’ for each
sample was used i.e. for each siRNA-treatment or compound treatment,
unstressed and stressed cell viability was measured by WST-1 assay,
then the ratio of the stressed to unstressed measurement for each
sample was calculated and is shown in Figs. 1, and 3–6.
3. Results
3.1. RAC1 knockdown sensitises RD and HT-1080 cells to ER-stress
Cancer cells are able to resist stress caused by oncogenic transfor-
mation and unfavourable micro-environmental conditions. These con-
ditions can induce ER-stress which activates the UPR and can lead to
apoptosis if not resolved [2]. Rho GTPases have been linked to evasion
of apoptosis [11] and there is evidence that they may be involved in
survival under ER-stress in C. elegans [19]. In addition, several Rho
GTPases bear oncogenic mutations in cancer [11]. We hypothesised
that human Rho GTPases may be involved in cell survival under ER-
stress and oncogenic mutation of Rho GTPases may protect cells from
ER-stress. We devised a strategy to test this using an siRNA screening
approach in two diﬀerent human soft-tissue sarcoma cell lines: RD cells
which have wild-type Rho GTPases and HT-1080 cells which contain an
oncogenic N92I RAC1 mutation [23]. Both these cell lines also contain
a Q61 NRAS mutation. Because the N92I RAC1 mutation is activating,
we would expect it to have a similar eﬀect to the P29S mutation in
melanoma. Cells were transfected with pools of siRNA targeting all 20
Rho GTPases plus the mitochondrial Rho GTPases RHOT1 and RHOT2.
ATF6 is an important pro-survival component of the UPR [8], so ATF6
siRNA was used as a positive control for increased sensitivity to ER-
stress. Non-targeting control siRNA (siCtrl pool) was used as a negative
control. To induce ER-stress, cells were treated with 2mM dithiothreitol
(DTT) which interferes with disulphide formation within the ER,
leading to ER-stress and UPR activation. It should be noted that several
siRNA pools aﬀected cell viability in unstressed conditions (Supple-
mentary Fig. S1A and S1B). Therefore, we calculated relative viability
compared to unstressed cells for each siRNA to assess sensitivity to
stress. In both cell lines, the positive control ATF6 siRNA sensitised cells
Table 1
Inhibitors, major targets and concentrations used in this study.
Inhibitor Major target(s) Concentration Reference
GSK2656157 PERK 50 and 500 nM [42]
Pictilisib (GDC-0941) PI3K 500 nM [43]
AKT inhibitor VIII AKT PH domain 5 μM [44]
AZD8055 MTOR 500 nM [45]
Apitolisib (GDC-0980) PI3K and MTOR 500 nM [46]
Selumetinib (AZD6244) MEK1 50 nM [47]
GDC-0879 BRAF/CRAF 50 nM [48]
RO5126766 BRAF/CRAF/MEK 50 nM [49]
SCH772984 ERK1/2 50 nM [50]
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to ER-stress, seen as lower relative viability after DTT treatment
(Fig. 1A and B). In RD cells (wild type GTPases), siRNA pools targeting
RHOA, RHOC RHOQ and RAC1 signiﬁcantly sensitised cells to DTT
treatment, with RHOA and RHOC having the strongest eﬀect (Fig. 1A).
In HT-1080 cells (N92I RAC1), while pools of siRNA against RHOA and
RHOQ had a small but signiﬁcant eﬀect on sensitivity to ER-stress,
siRNA against RAC1 had the strongest eﬀect and was comparable to the
ATF6 positive control (Fig. 1B). These results suggest that RHOA,
RHOC, RHOQ and RAC1 may be involved in cell survival under ER-
stress in wild-type cells, while oncogenic RAC1 mutation may overcome
this in HT-1080 cells where RAC1 is the predominant Rho GTPase in-
volved in ER-stress resistance. The observation that oncogenic RAC1
promotes resistance to ER-stress could be important for cancer treat-
ment because, targeting oncogenic RAC1 signalling may speciﬁcally
target cancer cells over wild-type cells. For this reason, we chose to
focus our research on the role of RAC1.
In order to validate the results from the screen, single siRNA oli-
gomers were used and cells were treated with two diﬀerent ER-stress
inducers: 2 mM DTT (as for the screen) or 20 μg/ml tunicamycin (Tm),
which induces ER-stress by inhibiting N-linked protein glycosylation
leading to a build-up of incorrectly processed protein within the ER.
Single oligomers aﬀected cell viability in unstressed cells
(Supplementary Fig. S1C and S1D), so viability relative to unstressed
cells for each single oligomer was used to assess sensitivity to stress. In
RD cells, RAC1_si1 and RAC1_si2 signiﬁcantly sensitised cells to DTT
treatment (Fig. 1C), and RAC1_si1, RAC1_si3 and RAC1_si4 slightly (but
signiﬁcantly) sensitised cells to Tm treatment (Fig. 1D). Results in RD
cells did not directly correlate with RAC1 expression as RAC1_si1,
RAC1_si2 and RAC1_si3 all knocked down the protein level to a similar
level but RAC1_si4 had a weaker eﬀect (Fig. 1G). In HT-1080 cells,
three out of four oligomers signiﬁcantly increased sensitivity to DTT
(Fig. 1E), and all oligomers signiﬁcantly increased sensitivity to Tm
(Fig. 1F). The three oligomers that consistently induced sensitivity to
ER-stress (RAC1_si1, RAC1_si2 and RAC1_si3) also corresponded to the
strongest knockdown in protein expression observed by western blot
(Fig. 1H). These observations agree with the siRNA screen and suggest
that oncogenic N92I RAC1 in HT-1080 cells promotes resistance to ER-
stress. To investigate the mechanism of this, we focussed attention on
HT-1080 cells and used two single siRNA oligomers for RAC1 knock-
down (RAC1_si1 and RAC1_si2) in subsequent experiments.
The WST-1 assay uses reduction of the WST-1 reagent as a measure
of cell viability, but does not directly measure cell death. Our next step
was to conﬁrm that RAC1 knockdown leads to increased apoptosis
under ER-stress by measuring cleavage of Poly [ADP Ribose]
Polymerase 1 (PARP1) and caspase-3, which can be used as a readout of
apoptosis [24]. We ﬁrst used a sandwich ELISA-based antibody array to
probe cell stress and apoptosis signalling pathways. Arrays detected
increased cleavage of PARP1 and caspase-3 in RAC1-depleted cells
under ER-stress compared to data from untransfected and siCtrl-trans-
fected cells (Fig. 2A and B), indicating that more apoptosis occurred in
RAC1-depleted cells under ER-stress. To conﬁrm these results, cleavage
of PARP1 and caspase-3 were measured in cell lysates. Western blots
conﬁrmed that cleavage of PARP1 and caspase-3 occurred more
strongly under ER-stress in RAC1-depleted cells than in siCtrl or un-
transfected cells (Fig. 2C). These data conﬁrm that RAC1 knockdown in
HT-1080 cells increases sensitivity to ER-stress by increasing apoptosis.
3.2. RAC1 knockdown alters the UPR in HT-1080 cells
Because cell fate under ER-stress is determined by the UPR [2], we
next sought to determine whether RAC1 knockdown in HT-1080 cells
inﬂuenced activation of the UPR. The UPR consists of IRE1/XBP1, ATF6
and PERK/EIF2S1/ATF4 arms [9]. To measure activation of the IRE1
arm of the UPR we used TaqMan quantitative PCR (qPCR) to measure
XBP1s and XBP1u transcripts as previously described [3]. As expected,
in untransfected and siCtrl cells, splicing of XBP1 mRNA was induced
by DTT treatment, observed as an increase in XBP1s (Fig. 3A) and de-
crease in XBP1u (Fig. 3B). Knockdown of RAC1 reduced the expression
of XBP1u (Fig. 3B), leading to a slight reduction in XBP1s at 2 h post-
DTT treatment, but this was not statistically signiﬁcant (Fig. 3A). This
suggests that oncogenic RAC1 may increase expression of XBP1u in
unstressed HT-1080 cells.
ATF6 activation was measured by observing the appearance of the
cleaved form of ATF6 by western blotting. ATF6 was cleaved after DTT
treatment in all samples, but the expression of cleaved ATF6 after DTT
treatment was higher in RAC1-depleted cells compared to controls
(Fig. 3C).
To measure activation of the PERK UPR arm, we used western
blotting to observe electrophoretic mobility shift of activated PERK,
phosphorylation of EIF2S1 at Serine 51 (a PERK substrate) and ex-
pression of ATF4 protein (downstream of EIF2S1 phosphorylation).
PERK was activated after DTT treatment (observed as an electro-
phoretic mobility shift to a slower band on the western blot) and this
was not aﬀected by RAC1 depletion compared to control cells (Fig. 3C),
although RAC1 knockdown induced an increase in total PERK protein
expression observed (Fig. 3C). Phosphorylation of EIF2S1 and expres-
sion of ATF4 protein both increased after DTT treatment in un-
transfected and siCtrl-transfected cells, and RAC1 knockdown altered
this response as follows: in unstressed conditions (0 h DTT), RAC1
knockdown led to a reduction in phosphorylated EIF2S1 (p-EIF2S1) and
a corresponding reduction in ATF4 compared to untransfected and
siCtrl cells (Fig. 3C). However, after DTT treatment p-EIF2S1 was
higher in RAC1-depleted cells compared to untransfected and siCtrl-
transfected cells, especially at the 2 h time-point, whereas ATF4 ex-
pression remained impaired (Fig. 3C).
The observation of higher p-EIF2S1, but lower ATF4 expression in
RAC1-depleted cells after 2 h DTT treatment is seemingly
Fig. 2. RAC1 knockdown in HT1080 human ﬁbrosarcoma cells causes increased caspase
activity under ER-stress. A and B, Mean ± standard deviation ﬂuorescence readings from
an ELISA-based antibody array measuring cleaved caspase-3 (A) and cleaved PARP1 (B)
in lysates from HT-1080 cells transfected with the indicated siRNA oligomers, followed by
treatment with 2mM DTT for 2 h (grey bars) or no treatment (black bars). C,
Representative western blots showing expression of PARP/cleaved PARP, cleaved cas-
pase-3, RAC1 and β-actin loading control in lysates from HT-1080 cells transfected with
the indicated siRNA, followed by treatment with 2mM DTT for 0, 2 or 4 h. Western blots
are representative of three independent experiments. U/T=untransfected.
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counterintuitive. We would expect ATF4 expression to increase with
EIF2S1 phosphorylation [9]. A possible explanation for this discrepancy
would be if the level of ATF4mRNA was reduced, so we measured ATF4
mRNA expression by qPCR in samples from RAC1-depleted and control
cells, with or without DTT treatment. In untransfected or siCtrl-trans-
fected cells, DTT treatment did not aﬀect the expression of ATF4 mRNA
(Fig. 3D). In RAC1-depleted cells, there was a signiﬁcant reduction in
ATF4 mRNA in unstressed conditions (0 h DTT), and the ATF4 mRNA
level became responsive to ER-stress—increasing with DTT treatment
(Fig. 3D). These data explain the observation that ATF4 protein ex-
pression is lower in RAC1-depleted cells despite the presence of in-
creased p-EIF2S1 after DTT treatment. They also suggest that N92I
RAC1 may drive overexpression of ATF4 mRNA in basal conditions,
because ATF4 transcript only responded to ER-stress when RAC1 was
depleted.
In the UPR, ATF4 activates transcription of DDIT3, a key pro-
apoptotic transcription factor that executes apoptosis caused by an
unresolved UPR [9]. We therefore tested whether RAC1 knockdown
Fig. 3. RAC1 knockdown alters the UPR in HT-1080 human ﬁbrosarcoma cells. A, B and D–F, mRNA expression of the indicated transcripts (TaqMan qPCR) in HT-1080 cells transfected
with the indicated siRNA and treated with 2mM DTT for the indicated times. C, western blots showing expression or phosphorylation of the indicated proteins in lysates from HT-1080
cells treated as in A (U/T=untransfected). G and H, western blots showing phosphorylation or expression of the indicated proteins in lysates from HT-1080 cells transfected with the
indicated siRNA or treated with the indicated concentration (nM) of GSK2656157 (PERKi) for 1 h, then either stressed with 2mM DTT for 2 h (G) or kept unstressed (H). I, Relative
viability (WST-1 assay) of HT-1080 cells transfected with the indicated siRNA targeting ATF4 and treated with 2mM DTT for 24 h. Data show relative viability of DTT-treated compared
to untreated cells for each siRNA. J, Western blots showing expression of ATF4 and β-actin loading control in lysates from HT-1080 cells transfected with the indicated siRNA
(-= untransfected, C= siCtrl). Western blots are representative of at least three independent experiments. Bar charts show means ± S.E.M. of data from three independent experiments.
* p < .05, ** p < .01, *** p < .001, unpaired t-test n= 3.
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leads to an inhibition of DDIT3 induction. qPCR measurements showed
that DTT treatment led to an increase in DDIT3mRNA expression which
was not signiﬁcantly aﬀected by the knockdown of RAC1 (Fig. 3E),
suggesting that DDIT3 is not part of the mechanism for the increased
sensitivity of RAC1-depleted cells to ER-stress.
We next investigated the mechanism for the observed modulation of
p-EIF2S1 caused by RAC1 knockdown. There is a known negative
feedback loop controlled by ATF4, which promotes the expression of
protein phosphatase 1 regulatory subunit 15A (PPP1R15A, also known
as GADD34) [25]. PPP1R15A activates serine/threonine phosphatase
PP1 to dephosphorylate EIF2S1 [26]. We hypothesised that the reduced
ATF4 mRNA level observed in RAC1-depleted cells may down-regulate
this negative feedback loop leading to EIF2S1 hyper-phosphorylation
upon ER-stress. To test this hypothesis, we ﬁrst measured the expression
of PPP1R15A in RAC1-depleted HT-1080 cells by qPCR. Compared to
siCtrl, RAC1 knockdown led to a signiﬁcant reduction of PPP1R15A in
unstressed cells which recovered after DTT treatment (Fig. 3F) corre-
lating with the data for ATF4 mRNA (Fig. 3D). This shows that the loss
of RAC1 in HT-1080 cells depletes a controlling component of the ne-
gative-feedback loop from ATF4 to EIF2S1 in resting conditions.
PPP1R15A expression was induced after ER-stress in all samples
(Fig. 3F), which would explain the peak of EIF2S1 at 2 h DTT followed
by dephosphorylation at 4 h as the negative feedback loop returned
(Fig. 3C). We hypothesised that RAC1-depleted cells may therefore be
primed for hyper-phosphorylation by PERK upon activation of the UPR.
If this is correct, inhibition of PERK should prevent the hyper-phos-
phorylation of EIF2S1. To test this, we used combined knockdown of
RAC1 and PERK, or RAC1 knockdown combined with the PERK in-
hibitor GSK2656157 (hereafter termed PERKi). Knockdown of RAC1
led to hyper-phosphorylation of EIF2S1 compared to control cells as
before (Fig. 3G), and knockdown or inhibition of PERK reduced EIF2S1
phosphorylation and inhibited the hyper-phosphorylation induced by
RAC1-depletion (Fig. 3G). These data agree with the hypothesis that
RAC1 knockdown impairs negative feedback on EIF2S1 phosphoryla-
tion leading to hyper-phosphorylation in early stages of ER-stress.
It might be expected that basal EIF2S1 phosphorylation would be
higher upon loss of the ATF4/PP1 feedback loop. However, basal
EIF2S1 phosphorylation was lower in RAC1-depleted cells (Fig. 3C). To
test whether the loss of PERK activity may be responsible for basal
EIF2S1 phosphorylation, we used siRNA and PERK inhibition. As seen
in Fig. 3C, RAC1 knockdown caused a reduction of p-EIF2S1 in these
unstressed conditions (Fig. 3H). However, EIF2S1 phosphorylation was
not aﬀected by PERK knockdown or small molecule inhibition sug-
gesting that PERK is not responsible for basal EIF2S1 phosphorylation
in HT-1080 cells.
Taken together, these data show that RAC1 depletion in HT-1080
cells alters UPR function: Under basal conditions, knockdown of RAC1
leads to a reduction in XBP1u and ATF4 mRNA, together with reduced
ATF4 protein and decreased phosphorylation of EIF2S1. After DTT
treatment, compared to control cells, RAC1-depleted HT-1080 cells
have lower ATF4 mRNA and protein, and a higher level of cleaved
ATF6, PERK protein and p-EIF2S1. We next investigated whether these
modulations of the UPR may cause increased sensitivity to ER-stress.
There is data already available for the roles of XBP1, PERK and ATF6 in
ER-stress in HT-1080 cells. We have previously shown that inhibition of
XBP1 splicing does not signiﬁcantly aﬀect HT-1080 cell survival under
DTT treatment [3]. In the present work we show that ATF6 knockdown
induces sensitivity to DTT treatment, (Fig. 1B) so we would not expect
increased ATF6 cleavage in RAC1-depleted cells to cause sensitivity to
ER-stress. In the case of PERK, inhibition of this kinase (and therefore
inhibition of ER-stress-induced EIF2S1 phosphorylation) has been
shown to sensitise HT-1080 cells to ER-stress [27]. Hence, we would not
expect EIF2S1 hyper-phosphorylation to increase sensitivity to ER-
stress. Therefore, we sought to determine whether reduced ATF4 sig-
nalling may cause the enhanced sensitivity to ER-stress in RAC1-de-
pleted cells. To do this, we tested whether knockdown of ATF4 would
mimic the eﬀect of RAC1 knockdown on cell viability under ER-stress.
Of the four siRNA oligomers targeting ATF4 tested, only one caused a
signiﬁcant decrease in cell viability after DTT treatment (Fig. 3I),
whereas all oligomers induced protein knockdown (Fig. 3J). This sug-
gests an oﬀ-target eﬀect of the oligomer ATF4_si3. Taken together with
the previous evidence using inhibitors of IRE1 and PERK [3, 27], the
present data from ATF6 knockdown (Fig. 1B) and ATF4 silencing
(Fig. 3I) suggest that despite the presence of an altered UPR in RAC1-
depleted HT-1080 cells, this is probably not the mechanism for their
increased sensitivity to ER-stress.
Because RAC1 is a regulator of the oncogenic and cell-protective
kinase signalling pathways PI3K/AKT/MTOR and RAF/MEK/ERK, we
next sought to determine how signalling through these pathways may
play a role in ER-stress resistance.
3.3. Inhibition of MEK/ERK signalling causes sensitivity to ER-stress in HT-
1080 and RD cells
RAC1 has previously been linked to PI3K/AKT/MTOR and RAF/
MEK/ERK signalling [12, 14, 15] and both these pathways can be im-
portant mechanisms of cancer cell evasion of apoptosis [16]. We hy-
pothesised that N92I RAC1 may drive anti-apoptotic signalling through
PI3K/AKT/MTOR and RAF/MEK/ERK in HT-1080 cells, leading to re-
sistance to ER-stress. To test this, we ﬁrst determined whether RAC1
knockdown leads to a reduction in the activity, and hence phosphor-
ylation of AKT, MEK1/2 or ERK1/2. Knockdown of RAC1 in HT-1080
cells led to reduced phosphorylation of AKTSER473 (p-AKT), MEK1/
2SER217/221 (p-MEK1/2) and ERK1/2THR202/TYR204 (p-ERK1/2) com-
pared to control cells (untransfected and siCtrl) (Fig. 4A). This suggests
that oncogenic RAC1 contributes to constitutive activation of AKT and
MEK/ERK in HT-1080 cells. To test whether reduced AKT or MEK/ERK
signalling may drive resistance to ER-stress, we used a panel of clini-
cally relevant small molecule inhibitors (Table 1). HT-1080 cells were
treated with each inhibitor for 1 h prior to treatment with DTT for 24 h.
Inhibitor remained present throughout the experiment and cell viability
was measured by WST-1 assay as before. PI3K/AKT/MTOR pathway
inhibitors had no signiﬁcant eﬀect on sensitivity to ER-stress (Fig. 4B),
despite strong inhibition of AKT phosphorylation (Fig. 4C) and sig-
niﬁcant eﬀects on cell viability in unstressed conditions (Supplemen-
tary Fig. S2A). In the case of RAF/MEK/ERK inhibitors, selumetinib,
RO5126766 and SCH772984, all reduced relative cell viability after
DTT treatment compared to DMSO vehicle control (Fig. 4D). GDC-0879
slightly increased relative viability after ER-stress but this was not
signiﬁcant (Fig. 4D). Interestingly, these results correlated with in-
hibition of ERK phosphorylation: selumetinib, RO5126766 and
SCH772984 all potently inhibited phosphorylation of ERK1/2, but
GDC-0879 caused paradoxical activation of ERK1/2 (Fig. 4E). The
phenomenon of paradoxical ERK1/2 activation caused by GDC-0879
activating wild type RAF has been previously described in other cell
lines [22]. RAF/MEK/ERK inhibition had no eﬀect on HT-1080 cell
viability in unstressed conditions (Supplementary Fig. S2B). These re-
sults indicate that MEK/ERK signalling may protect cells from ER-stress.
To conﬁrm that this eﬀect is not unique to HT-1080 cells, we tested the
eﬀect of RAF/MEK/ERK inhibition on cell viability under ER-stress in
RD cells. RD cells express oncogenic Q61H NRAS which would be ex-
pected to drive RAF/MEK/ERK activity. We treated RD cells in the same
way as HT-1080 cells for Fig. 4D and E and measured viability after
DTT treatment, and ERK1/2 phosphorylation as before. Data from RD
cells matched those from HT-1080 cells: Western blots showed the same
expected paradoxical ERK1/2 phosphorylation after GDC-0879 treat-
ment while the other inhibitors all strongly inhibited ERK1/2 (Fig. 4G).
Correlating with this, selumetinib, RO5126766 and SCH772984 all
reduced relative cell viability after DTT treatment compared to DMSO
vehicle control, and GDC-0879 slightly increased relative viability after
ER-stress (Fig. 4F). RAF/MEK/ERK inhibition had a weak eﬀect on RD
cell viability in unstressed conditions (Supplementary Fig. S2C). These
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data indicate that constitutive ERK activation in cancer cells drives
resistance to ER-stress.
3.4. Paradoxical ERK activation by RAF inhibition in NRAS-mutant cells
partially rescues the eﬀect of RAC1 knockdown on ER-stress
Our results suggest that N92I RAC1 drives resistance to ER-stress by
increasing MEK/ERK activity. We therefore hypothesised that the
paradoxical ERK activation caused by GDC-0879 may overcome the
eﬀect of RAC1 knockdown on sensitivity to ER-stress. To test this, HT-
1080 cells were transfected with control or RAC1 siRNA, then treated
with GDC-0879 or DMSO vehicle control for 1 h. Western blotting
showed that knockdown of RAC1 led to a reduction in p-MEK1/2 and p-
ERK1/2, and 50 nM GDC-0879 caused hyper-phosphorylation of
MEK1/2 and ERK1/2 in both control and RAC1-depleted cells (Fig. 5A).
Measurements of cell viability (WST-1 assay) after 24 h DTT treatment
showed that 50 nM GDC-0879 partially rescued the eﬀect of RAC1
knockdown on sensitivity to ER-stress (Fig. 5B). These results conﬁrm
the hypothesis that the loss of MEK/ERK activity is at least partly re-
sponsible for the eﬀect of RAC1 knockdown on sensitivity to ER-stress
in HT-1080 cells.
3.5. Knockdown of NRAS induces sensitivity to ER-stress in NRAS mutant
cell lines
Our data show that RAC1 expression in HT-1080 cells is required for
full constitutive activation of the MEK/ERK signalling pathway. A
known activator of MEK/ERK signalling in cancer is oncogenic NRAS,
which directly activates the kinase RAF upstream of MEK [28]. There is
evidence that aberrant signalling and cell proliferation caused by Q61K
NRAS in melanocytes is dependent on RAC1 [29]. HT-1080 cells ex-
press oncogenic mutants of both RAC1 (N92I) and NRAS (Q61K) [23],
so we next sought to determine whether the presence of N92I RAC1 in
this cell line would promote the constitutive activation of MEK/ERK
regardless of the expression of NRAS. Each of four diﬀerent siRNA
oligomers successfully knocked down NRAS protein and strongly re-
duced the amount of phosphorylated ERK1/2 (Fig. 6A). We next sought
to investigate whether NRAS or RAC1 has a stronger eﬀect on con-
stitutive ERK1/2 activity, or whether the expression of NRAS or RAC1 is
dependent on the other. To do this, we co-transfected HT-1080 cells
with two diﬀerent combinations of siRNA targeting both NRAS or
RAC1, or the single oligomers alone. Our results showed that RAC1 and
NRAS are not dependent on each other for expression, as RAC1 oligo-
mers did not knock down NRAS and vice versa (Fig. 6B). Knockdown of
RAC1 or NRAS had a similar eﬀect on the level of p-ERK1/2, as the
combined knockdown gave no further reduction compared to single
oligomers (Fig. 6B). These data show that both RAC1 (N92I) and NRAS
(Q61K) are required for constitutive activation of MEK/ERK signalling
in HT-1080 cells. Because we have shown that inhibition of MEK/ERK
sensitises HT-1080 cells to ER-stress (Fig. 4), and NRAS knockdown
strongly reduced MEK/ERK activity (Fig. 6A), we hypothesised that
NRAS knockdown would make HT-1080 cells more sensitive to ER-
stress. We tested this by using siRNA to reduce NRAS expression in HT-
1080 cells, then treating cells with two diﬀerent ER-stressors (2 mM
DTT or 20 μg/ml Tm) for 24 h. For both stressors, all siRNA oligomers
reduced the viability of stressed cells compared to unstressed, and this
was signiﬁcant for three (DTT treatment) or two (Tm treatment) oli-
gomers (Fig. 6C and D). The RD cell line expresses a Q61H mutant
NRAS which we would expect to drive ERK1/2 activity. Therefore, we
tested whether NRAS knockdown in RD cells would lead to a reduction
in ERK1/2 activity combined with increased sensitivity to ER-stress. RD
cells were treated in the same way as the HT-1080 cells for Fig. 6A, C
and D. Results from RD cells were similar to those from HT-1080 cells.
Each siRNA oligomer reduced NRAS protein expression and ERK1/2
phosphorylation (Fig. 6E) and NRAS-depleted cells were also more
sensitive to both DTT and Tm treatment, as NRAS-depleted cells had a
Fig. 4. Inhibition of MEK or ERK, but not PI3K, AKT or MTOR, causes sensitivity to ER-
stress in HT-1080 human ﬁbrosarcoma cells. A, Western blots showing expression or
phosphorylation of the indicated proteins in lysates from HT-1080 cells transfected with
the indicated siRNA (-= untransfected, C= siCtrl). B, D and F, Relative viability mea-
surements (WST-1 assay) of HT-1080 cells (B and D) or RD cells (F) treated with the
indicated inhibitors for 1 h, then 2mM DTT for 24 h. Data show relative viability of DTT-
treated compared to untreated cells for each inhibitor. C, E and G, Western blots showing
expression and phosphorylation of the indicated proteins in lysates from HT-1080 cells (C
and E) or RD cells (G) treated with the indicated inhibitors, or DMSO vehicle control, for
1 h. Western blots are representative of at least three experiments. Bar charts show means
and S.E.M. of data from three independent experiments. * p < .05, ** p < .01, ***
p < .001, unpaired t-test comparing to DMSO only, n= 3.
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lower relative viability than control cells (Fig. 6F and G). Interestingly,
single siRNA oligomers targeting NRAS had only weak eﬀects on cell
viability in the absence of ER-stress suggesting NRAS is not the only
driver of HT-1080 or RD cell proliferation (Supplementary Fig. S3A and
B). In agreement with cell viability data, knockdown of NRAS caused an
increase in apoptosis after DTT treatment of both HT-1080 and RD cells,
observed as an increase in cleaved PARP and cleaved caspase-3 (Fig. 6H
and I). Together, these results suggest that NRAS drives resistance to
ER-stress in Q61 NRAS mutant cell lines. Data from HT-1080 cells show
that the presence of N92I RAC1 alone is not suﬃcient to fully activate
MEK/ERK and protect against ER-stress in the absence of Q61K NRAS.
4. Discussion
Cancer cells are able to survive under micro-environmental condi-
tions that lead to ER-stress. The mechanisms underlying this are likely
to be multifaceted and dependent on the genetic background of the
cancer cells. The cell signalling response that controls the balance be-
tween cell survival and cell death upon ER-stress is the UPR [9] and
previous studies have shown that this plays an important role in cancer
cell adaption to stress and cancer development [30]. Many Rho GTPases
are strongly linked to cancer through mutation or overexpression [11,
20]. In C. elegans, knockout of a Rho GTPase impairs the UPR [19],
suggesting that a human Rho GTPase may have a similar role. In the
present study, we examined the role of Rho GTPases in cancer cell
Fig. 5. ERK activation induced by the BRAF/CRAF inhibitor
GDC-0879 partially rescues the eﬀect of RAC1 knockdown on
ER-stress sensitivity. A, Western blots showing phosphorylation
and expression of the indicated proteins in lysates from HT-1080
cells transfected with the indicated siRNA for 48 h followed by
50 nM GDC-0879 or DMSO vehicle control for 1 h (-= un-
transfected, C= siCtrl). B, Relative viability measurements
(Wst-1 assay) of HT-1080 cells transfected with the indicated
siRNA for 48 h, then treated with 50 nM GDC-0879 (grey bars)
or DMSO vehicle control (black bars) for 1 h, then 2mM DTT for
24 h. Data show relative viability of DTT-treated compared to
untreated cells for each inhibitor or siRNA treatment (U/
T=untransfected). Western blots are representative of three
experiments. Bar charts show means ± S.E.M. of data from
three independent experiments. * p < .05, unpaired t-test
n= 3.
Fig. 6. Knockdown of NRAS causes sensitivity to ER-stress in HT-1080 and RD human cancer cell lines. A and E, western blots showing expression and phosphorylation of the indicated
proteins in lysates from HT-1080 cells (A) or RD cells (E) transfected with the indicated siRNA. B, Western blots showing phosphorylation or expression of the indicated proteins in lysates
from HT-1080 cells transfected with the indicated siRNA. C, D, F and G, Relative viability (WST-1 assay) of HT-1080 cells (C and D) or RD cells (F and G) after transfection with the
indicated siRNA, followed by treatment with 2mM DTT (C and F) or 20 μg/ml Tm (D and G) for 24 h. Data show mean and S.E.M. of relative viability of stressed (DTT or Tm) compared to
unstressed cells for each siRNA. * p < .05, ** p < .01, *** p < .001, unpaired t-test comparing to siCtrl, n= 3. H and I, western blots showing expression of the indicated proteins in
lysates from HT-1080 cells (H) or RD cells (I) transfected with the indicated siRNA, then treated with DTT for the indicated times. U/T=untransfected, western blots are representative
of three experiments.
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survival under ER-stress using siRNA screening and in vitro chemical
ER-stress inducers. Our siRNA screening results showed that RAC1 was
particularly important in cell survival under ER-stress in HT-1080 cells
which express an oncogenic RAC1 mutant, compared to RD cells which
express wild type RAC1. In RD cells, RHOA and RHOC knockdown had
a stronger eﬀect on sensitivity to ER-stress than RAC1 knockdown.
Therefore, further study of RHOA and RHOC in the stress response of
wild-type cells is warranted. Rho GTPases have been well characterised
as modulators of the cytoskeleton, including control of myosin activity
[20] and it has been suggested that Myosin IIB controls the clustering of
IRE1—a key component of the UPR [21]. It may be the case that RHOA
and/or RHOC control the function of Myosin IIB in ER-stress.
Because the UPR is the key response controlling cell fate under ER-
stress, we determined the eﬀect of RAC1 depletion on UPR activity in
HT-1080 cells. In unstressed conditions, knockdown of RAC1 led to a
reduction in XBP1u and ATF4 and PPP1R15A mRNA expression.
Further work is required to determine the mechanism of this reduction.
It is possible that N92I RAC1 drives a regulatory network that controls
XBP1 and ATF4 transcription. RAC1 expression has previously been
linked to transcription factor expression in glioma [31], and while the
RNAseq data presented did not link ATF4 and XBP1 to RAC1 expression,
the association may depend on cell type and genetic background. Our
data show that RAC1 knockdown led to PERK-dependent hyper-phos-
phorylation of EIF2S1 shortly after induction of ER-stress, which is
accounted for by impaired expression of the ATF4/PPP1R15A negative
feedback loop. It is also possible that the observed increased PERK
expression in RAC1-depleted cells contributes to the hyper-phosphor-
ylation. In unstressed conditions, despite the loss of ATF4/PPP1R15,
EIF2S1 phosphorylation was lower in RAC1-depleted cells compared to
control cells. We show using siRNA and PERK inhibition that PERK is
not responsible for basal EIF2S1 phosphorylation in these cells, in
agreement with a previous study [27]. These ﬁndings imply that a
diﬀerent kinase acts downstream of RAC1 to phosphorylate EIF2S1 in
basal conditions. There are three other EIF2S1 kinases in humans:
EIF2AK1 (also known as HRI), EIF2AK2 (also known as PKR) and
EIF2AK4 (also known as GCN2). A possible candidate for basal phos-
phorylation in HT-1080 is GCN2, as GCN2 knockout mouse embryonic
ﬁbroblasts display reduced EIF2S1 phosphorylation [32]. Although the
UPR was altered by RAC1 knockdown, these changes were not asso-
ciated with the phenotype of increased sensitivity to ER-stress. We
showed that the small molecule PERK inhibitor GSK2656157 (PERKi)
inhibits EIF2S1 hyper-phosphorylation in RAC1-depleted cells. How-
ever, it is known that inhibition of PERK has a sensitising eﬀect rather
than a protective eﬀect under ER-stress [27]. In the case of XBP1 spli-
cing, we have previously shown that inhibition of IRE1 does not sen-
sitise HT-1080 cells to DTT treatment [3]. In the present work, we
tested the eﬀect of ATF4 knockdown on ER-stress sensitivity and found
that there was no consistent signiﬁcant eﬀect. In addition, DDIT3 ex-
pression was not signiﬁcantly diﬀerent between RAC1 knockdown and
control cells, meaning that the apoptotic signal downstream of the UPR
was still active.
Because the UPR was not responsible for the phenotype of ER-stress-
sensitivity of RAC1-depleted cells, we turned our attention to RAC1/
cancer-linked kinase signalling pathways PI3K/AKT/MTOR and RAF/
MEK/ERK [12, 14, 15]. One function of these signalling pathways is in
the avoidance of apoptosis, an important hallmark of cancer [10, 16].
Knockdown of RAC1 led to a reduction in phosphorylation/activity, of
AKT, MEK1/2 and ERK1/2 in unstressed conditions. The signalling
mechanisms that link RAC1 to AKT, MEK and ERK are not yet fully
determined. RAC1 activates p21-activated kinase 1 (PAK1) and it has
been proposed that RAC1/PAK1 can promote MEK activity by direct
phosphorylation [33] and through a scaﬀold function [34]. RAC1/
PAK1 has also been linked to PI3K and AKT, potentially through re-
active oxygen species [35] but a proven mechanism has so far been
elusive. The PI3K/AKT/MTOR and RAF/MEK/ERK pathways are im-
portant therapeutic targets in cancer and therefore there are numerous
clinically important small molecule inhibitors available to examine
their function [36]. We used a panel of inhibitors and found that in-
hibition of MEK/ERK but not PI3K/AKT/MTOR caused sensitivity to
ER-stress. Sensitivity to ER-stress correlated with inhibition of ERK1/2
Fig. 7. Graphical representation of ﬁndings from HT-1080
cells. A, In basal conditions, N92I-RAC1 promotes increased
p-MEK1/2 and p-ERK1/2 and p-EIF2S1. Overexpression of
ATF4 contributes to p-EIF2S1 homeostasis. B, Upon RAC1
knockdown, reduced p-MEK1/2 and p-ERK1/2 leads to re-
duced cell proliferation. There is a loss of basal p-EIF2S1
which is not rescued by the concomitant loss of ATF4 ex-
pression. C, ER-stress in untransfected cells leads to phos-
phorylation of EIF2S1 which is quickly attenuated by the
N92I-RAC1-driven overexpression of ATF4. N92I-RAC1-
dependent p-MEK1/2 and p-ERK1/2 promotes cell survival.
D, Loss of constitutive ATF4 expression in RAC1-depleted
cells leads to hyper-phosphorylation of EIF2S1 by PERK in
ER-stressed cells because negative feedback is attenuated.
Reduced pMEK1/2 and p-ERK1/2 causes increased sensi-
tivity to stress. Bold arrows represent comparison with
corresponding untransfected cells. Red arrows represent
phosphorylation, blue arrows represent expression. (For
interpretation of the references to colour in this ﬁgure le-
gend, the reader is referred to the web version of this ar-
ticle.)
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phosphorylation. We observed the expected paradoxical activation of
ERK induced by GDC-0879 (in a similar way to that described for other
cell lines [22]) and this protected RD cells against ER-stress, and par-
tially rescued the eﬀect of RAC1 knockdown on ER-stress in HT-1080
cells. We conclude that the loss of ERK activity is part of the mechanism
for increased sensitivity to ER-stress in RAC1-depleted HT-1080 cells
but because this rescue eﬀect was only partial, it is likely that there is
also another ER-stress-survival signalling pathway that is perturbed by
loss of RAC1. A summary of the eﬀects of N92I-RAC1 knockdown in HT-
1080 cells is shown in Fig. 7.
ERK signalling is an important part of the mechanism of oncogenic
NRAS, and both HT-1080 cells and RD cells contain an oncogenic Q61
NRAS mutation, so we investigated whether knockdown of NRAS would
produce a similar phenotype to knockdown of RAC1 or inhibition of
MEK/ERK. Knockdown of NRAS in both HT-1080 and RD cell lines
signiﬁcantly caused sensitivity of cells to ER-stress and a reduction in
phosphorylation of MEK1 and ERK1/2. Interestingly, we found that
simultaneous knockdown of RAC1 and NRAS in HT-1080 cells did not
have a stronger eﬀect on ERK1/2 phosphorylation than either siRNA on
their own. This shows that oncogenic RAC1 and NRAS are co-dependent
to activate MEK/ERK signalling in HT-1080 cells. In agreement with
this, it has previously been reported that signalling and cell growth
caused by Q61K NRAS in melanocytes is dependent on RAC1 [29]. The
mechanism for this co-dependence remains to be determined. In RD
cells, RAC1 knockdown had a weaker eﬀect on sensitivity to ER-stress
than NRAS knockdown. This suggests that NRAS may not depend on
RAC1 in this cell line (although eﬃciency of knockdown may have an
eﬀect). Instead, RHOA, RHOC, and to a lesser extent RHOQ sig-
niﬁcantly reduced viability under ER-stress in RD cells so it would be of
interest to determine whether one of these aﬀects ERK phosphorylation
and cooperates with NRAS. A connection between NRAS and RHOA is
not unprecedented, as loss of NRAS in C-cell thyroid adenomas in mice
leads to increased RHOA activity [37].
Taken together, our data show that oncogenic mutant RAC1 and
NRAS drive resistance to ER-stress by activating MEK/ERK signalling.
These ﬁndings are important because activation of the MEK/ERK
pathway is strongly associated with cancer. It has been estimated that
one third of all cancers contain an upregulated MAPK signalling
pathway [38] and around 16% of all cancers contain a RAS mutation
[39]. This has led to the discovery and development of multiple ther-
apeutic kinase inhibitors that target MEK/ERK signalling to prevent
cancer cell proliferation and promote apoptosis [36]. Our data suggest
that the use of MEK/ERK inhibitors may sensitise cancer cells to ER-
stress, providing an opportunity to increase apoptosis by combining
MEK/ERK inhibition with drugs that induce ER-stress, for example
proteasome inhibitors or chaperone inhibitors [40]. Indeed, there is
published evidence that agrees with this hypothesis: combination of
RAF/MEK/ERK inhibition with HSP90 inhibition has a synergistic ef-
fect on myeloma cells [41]. The present study provides novel insight
into the mechanisms of cancer cell survival under ER-stress and sheds
light onto the importance of the MEK/ERK pathway in this process.
5. Conclusions
• RAC1 knockdown sensitises soft tissue sarcoma cells to ER-stress.
• In HT-1080 ﬁbrosarcoma cells, N92I Rac1 controls UPR homeostasis
by promoting phosphorylation of EIF2S1 and driving expression of
ATF4.
• N92I Rac1 leads to constitutive activation of AKT and MEK/ERK
signalling.
• In soft tissue sarcoma cell lines with constitutively active NRAS,
inhibition of MEK/ERK, or knockdown of NRAS, sensitises cells to
ER-stress.
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